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Definitive endoderm differentiation is crucial for generating respiratory and gastrointestinal organs including 
pancreas and liver. However, whether epigenetic regulation contributes to this process is unknown. Here, we show 
that the H3K27me3 demethylases KDM6A and KDM6B play an important role in endoderm differentiation from hu-
man ESCs. Knockdown of KDM6A or KDM6B impairs endoderm differentiation, which can be rescued by sequen-
tial treatment with WNT agonist and antagonist. KDM6A and KDM6B contribute to the activation of WNT3 and 
DKK1 at different differentiation stages when WNT3 and DKK1 are required for mesendoderm and definitive en-
doderm differentiation, respectively. Our study not only uncovers an important role of the H3K27me3 demethylases 
in definitive endoderm differentiation, but also reveals that they achieve this through modulating the WNT signaling 
pathway.
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Introduction
Embryonic stem cells (ESCs) are promising sources 
for cell therapy due to their pluripotency and unlimited 
self-renewal capacity [1]. Definitive endoderm differ-
entiation is the first critical step for generating respira-
tory and gastrointestinal tracts as well as all of their as-
sociated organ/tissues including pancreas and liver [2]. 
Segregation of endoderm germ layer from mesoderm 
and ectoderm is one of the first cell fate decisions made 
in development. Definitive endoderm induction is con-
trolled by the evolutionarily conserved Nodal/TGF-β sig-
naling pathway [2, 3]. Activin A is a key induction factor 
for ESC differentiation into definitive endoderm lineages 
[4, 5]. In addition, molecules of other signaling path-
ways including WNT, FGF, BMP and PI3K have also 
been shown to contribute to endoderm differentiation 
[6]. Interestingly, different human ESC lines also exhibit 
different lineage-specific differentiation capacity due 
to the genetic and epigenetic differences [7]. Although 
growth factors, such as activin A, can effectively induce 
definitive endoderm differentiation from human ESCs, 
the underlying mechanism, particularly the epigenetic 
mechanism is largely unknown. 
Histone methylation plays an important role in di-
verse biological processes including transcription [8]. 
Although histone methylation can function in both gene 
activation and repression, Polycomb repressive complex 
2 (PRC2)-mediated histone H3 lysine 27 trimethylation 
(H3K27me3) has been mainly linked to transcription 
repression [9]. Given the role of H3K27 methylation in 
silencing lineage-specific differentiation genes in ESCs 
and that H3K27me3 mark can be actively removed by 
demethylases, H3K27me3 demethylases likely play an 
important role in driving ESC differentiation. Indeed, 
KDM6A (also named UTX) and KDM6B (also named 
JMJD3) have been shown to be involved in transcription-
al activation in normal development [10-13]. Recently, 
Kdm6a and Kdm6b also have been shown to play an im-
portant role in cardiac [14] and M2 macrophage [15] de-
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velopment, respectively. Previous studies have revealed 
that ESCs contain bivalent chromatin domains that har-
bor both repressive (H3K27me3) and active (H3K4me3) 
marks and these bivalent domains play important roles in 
maintaining the balance between self-renewal and differ-
entiation [16-18]. Here we demonstrate that KDM6A and 
KDM6B contribute to definitive endoderm differentia-
tion by modulating the WNT signaling pathway. 
Results and Discussion
H3K27me3 demethylases KDM6A and KDM6B are up-
regulated upon definitive endoderm differentiation
Consistently, we found that the expression levels of 
definitive endoderm genes are markedly increased while 
pluripotency genes are greatly reduced upon activin A 
treatment of the HUES8 ESCs (Supplementary informa-
tion, Figure S1A-S1B). Because activin A-induced dif-
ferentiation does not generate homogenous cell popula-
tion (Supplementary information, Figure S1B), we used 
CD184 (also named CXCR4), a well-known definitive 
endoderm marker [4, 19-21], to sort the cell population 
and confirmed successful endoderm differentiation by 
RT-qPCR analysis (Supplementary information, Figure 
S1C). In addition to CD184, another report [20] used 
both CD184 and CD117 (also named c-KIT) to mark the 
definitive endoderm cell population. Interestingly, we 
found that CD184+ cells are almost always CD117+ in 
our differentiation system (Supplementary information, 
Figure S1D). These analyses confirm that CD184 can 
serve as a marker for definitive endoderm differentiation 
in our human ESC differentiation system.
To explore a potential role of H3K27me3-related en-
zymes in definitive endoderm differentiation, we asked 
whether these enzymes are enriched in purified definitive 
endoderm cells. RT-qPCR analysis demonstrates both 
KDM6A and KDM6B levels are significantly higher in 
CD184-positive cells compared to that in CD184-neg-
ative cell population (Figure 1A, P < 0.05). In contrast, 
no significant difference in the level of EZH1 or EZH2 
is detected between these two cell populations (Figure 
1A). Consistent with a potential role of KDM6A and 
KDM6B in endoderm differentiation, we found that both 
are upregulated (>20-fold for KDM6B and ~3-fold for 
KDM6A) during endoderm differentiation (Figure 1B). 
KDM6A or KDM6B knockdown impairs definitive endo-
derm differentiation
To explore a potential role of KDM6A and KDM6B 
in endoderm differentiation, we generated lentiviral 
shRNA knockdown constructs that target KDM6A or 
KDM6B, and established stable KDM6A and KDM6B 
knockdown cell lines. RT-qPCR analysis revealed that 
we achieved 60%-70% of knockdown in these cell lines 
(Supplementary information, Figure S2). To evaluate 
whether knockdown of KDM6A or KDM6B affects 
definitive endoderm differentiation, we subjected the 
KDM6A or KDM6B knockdown cell lines to activin A 
treatment. FACS analysis indicated that KDM6A or KD-
M6B knockdown cell lines exhibited lower percentage 
of CD184-positive cells compared to the control (Figure 
1C-1D) indicating impairment of endoderm differentia-
tion. Consistently, RT-qPCR analysis revealed decreased 
expression of endoderm marker genes, such as FOXA2, 
GATA6, GSC, NCAD and SOX17, upon KDM6A or KD-
M6B knockdown (Figure 1E). FACS analysis and im-
munofluorescence staining further confirmed impairment 
in endoderm differentiation upon KDM6A or KDM6B 
knockdown (Supplementary information, Figure S3). To 
demonstrate that the knockdown effect is specific and to 
evaluate whether the H3K27me3 demethylase activity of 
KDM6 is required for efficient endoderm differentiation, 
we attempted to rescue the endoderm differentiation de-
fects with wild-type and catalytic mutant mouse Kdm6b. 
Results shown in Figure 1F demonstrate that wild-type, 
but not the catalytic mutant, Kdm6b partially rescued 
the endoderm differentiation defect. This result not only 
confirms the knockdown specificity, but also indicates 
that the demethylase activity of KDM6 is important for 
endoderm differentiation. 
Defective endoderm differentiation is linked to defective 
WNT signaling
The fact that KDM6A or KDM6B depletion impairs 
definitive endoderm differentiation prompted us to ask 
whether the defect is caused by defective ESC main-
tenance. Characterization of the KDM6A or KDM6B 
knockdown ESCs revealed that they exhibit normal hu-
man ESC morphology, and express pluripotency markers 
such as NANOG, SOX2, SSEA4 and OCT4 (Supple-
mentary information, Figure S4A and S4C). RT-qPCR 
analysis demonstrates that the expression levels of pluri-
potency genes or the three germ layer lineage markers 
are not significantly altered in the KDM6A or KDM6B 
knockdown cells (Supplementary information, Figure 
S4B). Consistent with a recent report demonstrating 
that Utx knockout does not affect mouse ESC pluripo-
tency [14], these studies indicate that depletion of either 
KDM6A or KDM6B does not affect human ESC main-
tenance. We then asked whether KDM6A or KDM6B 
knockdown affect signaling pathways important for en-
doderm differentiation. 
WNT, BMP and FGF signaling pathways play impor-
tant roles in modulating definitive endoderm differentia-
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Figure 1 KDM6A and KDM6B contribute to definitive endoderm differentiation from human ESCs. (A) 4 days after differen-
tiation, CD184-positive definitive endoderm cells and CD184-negative cells were analyzed to compare the gene expression 
levels of H3K27me3 methyltransferases (EZH1 and EZH2) and demethylases (KDM6A and KDM6B). The P values are 
derived from three independent experiments. The expression level in CD184-negative cells is set as 1. (B) Relative expres-
sion levels of KDM6A and KDM6B during 6-day activin A-induced definitive endoderm differentiation. The expression level in 
undifferentiated human ESCs is set as 1. (C) Representative flow cytometric data showing the percentage of CD184-positive 
cells in control and KDM6A or KDM6B knockdown ESCs upon 4-day definitive endoderm differentiation. (D) Quantification of 
the CD184-positive cell populations in control and KDM6A or KDM6B knockdown ESCs upon 4-day definitive endoderm dif-
ferentiation. The statistical values are # P > 0.05; *** P < 0.001. (E) RT-qPCR analysis of the expression levels of endoderm 
markers in control and KDM6A or KDM6B knockdown human ESCs upon 4-day definitive endoderm differentiation. (F) En-
forced expression of wild-type mouse Kdm6b, but not its catalytic mutant, could rescue the endoderm differentiation defect of 
KDM6B knockdown. Upper panel showed similar exogeneous expression levels of wild-type and mutant Kdm6b; lower panel 
showed percentage of CD184-positive cells in KDM6B knockdown cells transfected with control, wild-type or catalytic mutant 
mouse Kdm6b upon 4-day activin A treatment. The statistical values are # P > 0.05; ** P < 0.01; *** P < 0.001.
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tion [6]. To determine which of these signaling pathways 
is relevant to the endoderm differentiation defect caused 
by KDM6A or KDM6B knockdown, we asked whether 
the differentiation defect could be overcome by treatment 
with agonists of these pathways. We found that WNT 
agonists, but not BMP or FGF agonists, partially rescued 
the endoderm differentiation defect phenotype (Figure 
2A), indicating that the WNT pathway might be relevant. 
Consistent with this notion, analysis of previous ChIP-
seq results [16, 17] of H3K27me3-enriched genes in hu-
man ESCs revealed that the WNT signaling pathway is 
highly enriched for H3K27me3 (Supplementary informa-
tion, Figure S5, P = 0.00007), making genes of the WNT 
pathway likely relevant targets for KDM6A or KDM6B 
regulation. Consequently, we focused our attention on 
the WNT pathway.
KDM6A/KDM6B contributes to definitive endoderm dif-
ferentiation through modulating WNT pathway
In human ESCs, activation of Wnt/β-catenin signaling 
promotes loss of self-renewal and drives mesoderm lin-
eage differentiation [22]. Moreover, Wnt3a was utilized 
in the first days to promote mesendoderm differentiation 
but was removed in the later stage [23]. These studies 
suggest that WNT signaling is required for mesendoderm 
differentiation but continuous activation of this pathway 
would lead to mesoderm differentiation. Consistent with 
this, we found that inhibition of WNT signaling could 
also facilitate definitive endoderm differentiation from 
human ESC-derived mesendoderm (see data below). 
Given the role of WNT signaling in mesendoderm and 
further definitive endoderm differentiation, we asked 
whether manipulation of WNT signaling at different dif-
ferentiation stages could rescue the endoderm differen-
tiation defect caused by KDM6A/KDM6B knockdown. 
FACS sorting and quantification of the CD184-positive 
cell population after activin A-induced endoderm differ-
entiation under various WNT agonist (Wnt3a) or antago-
nist (Xav939) treatments revealed that the differentiation 
defects caused by KDM6A or KDM6B knockdown can 
Figure 2 KDM6A/KDM6B contributes to definitive endoderm differentiation through modulating WNT signaling pathway. (A) 
KDM6A or KDM6B knockdown-caused endoderm differentiation defects can be partially rescued by the addition of the growth 
factor Wnt3a (10 and 50 ng/ml), but not bFGF (2 and 10 ng/ml) or BMP4 (5 ng/ml) to the activin A-induced differentiation pro-
cedure. The statistical values are * P < 0.05; ** P < 0.01; *** P < 0.001. (B) KDM6A or KDM6B knockdown-caused endoderm 
differentiation defects can be rescued by addition of the WNT agonist Wnt3a (50 ng/ml) at the first 2-day differentiation or ad-
dition of WNT antagonist Xav939 (1 μM) at the late 2-day differentiation individually or in combination in the activin A-based 
endoderm differentiation. Percentage of CD184-positive cells is measured after 4-day differentiation and presented in the 
various treatments. The statistical values are # P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001.
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be rescued either by the use of the WNT agonist at the 
early differentiation stage (Figure 2B, compare A-A with 
AW-A treatment) or partially rescued by the use of WNT 
antagonist at the late differentiation stage (Figure 2B, 
compare A-A with A-AX treatment). Under the condition 
of sequential treatment with WNT agonist followed by 
antagonist, the differentiation defects are completely res-
cued (Figure 2B, compare A-A with AW-AX treatment). 
Figure 3 WNT3 is a KDM6A/KDM6B target contributing to early endoderm differentiation. (A) RT-qPCR analysis of the ex-
pression of 7 H3K27me3-enriched WNT ligand genes during definitive endoderm differentiation. WNT2, WNT2B, WNT5B, 
WNT6, WNT9B, WNT10A and WNT16 are not detectable. Expression levels are related to day 0. Data presented is the aver-
age of three independent experiments with error bars. (B) RT-qPCR analysis demonstrates downregulation of WNT3 expres-
sion upon KDM6A or KDM6B knockdown. (C) ChIP analysis demonstrates increased H3K27me3 level, but not H3K4me3, at 
the WNT3 gene promoter upon KDM6A or KDM6B knockdown. The analysis was performed at the beginning of differentia-
tion. (D) Activin A-induced endoderm differentiation is compromised by WNT3 knockdown, which can be rescued by the addi-
tion of the WNT agonist Wnt3a. The differentiation efficiency is measured by quantification of CD184-positive cell population 
after 4-day activin A-based endoderm differentiation.
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These results indicate that the function of KDM6A and 
KDM6B in endoderm differentiation is largely mediated 
through the WNT signaling pathway.  
WNT3 is a KDM6A/KDM6B target contributing to the 
early stage of endoderm differentiation
Results presented in Figure 2B demonstrate that deple-
tion of KDM6A or KDM6B impairs WNT signaling at an 
early stage of differentiation but enhances WNT signal-
ing at a late differentiation stage, suggesting that differ-
ent KDM6A/KDM6B target genes may mediate the early 
and late differentiation effects, respectively. Because 
KDM6A and KDM6B remove the H3K27me3 repressive 
mark, they likely function in gene activation. Consider-
ing the fact that WNT agonist in the early differentiation 
stage and WNT antagonist in the late differentiation stage 
can partially rescue impaired definitive endoderm dif-
ferentiation phenotype, it is likely that KDM6A/KDM6B 
upregulate WNT activator at the early stage and WNT 
repressor at the late stage of endoderm differentiation. 
To identify target genes of KDM6A/KDM6B in the 
early stage, we analyzed the expression of 14 WNT li-
gand genes that are enriched for H3K27me3 in human 
ESCs (Supplementary information, Figure S5). Among 
these genes, only seven are detectable. Of which, WNT3 
exhibits the highest upregulation at 1 day of differentia-
tion (Figure 3A). Consistent with the notion that WNT3 
is an important KDM6A/KDM6B target, knockdown 
of KDM6A or KDM6B downregulates WNT3 expres-
sion (Figure 3B). In addition, ChIP analysis indicates 
Figure 4 DKK1 is a KDM6A/KDM6B target contributing to late endoderm differentiation. (A) RT-qPCR analysis of the ex-
pression of H3K27me3-enriched WNT antagonist genes during definitive endoderm differentiation. SFRP4 is not detectable. 
Expression levels are related to day 0. Data presented is the average of three independent experiments with error bars. 
(B) RT-qPCR analysis demonstrates downregulation of DKK1 expression upon KDM6A or KDM6B knockdown. (C) ChIP 
analysis demonstrates increased H3K27me3 level, but not H3K4me3, at the DKK1 gene enhancer upon KDM6A or KDM6B 
knockdown. The analysis was performed at the beginning of the second stage of differentiation. (D) Activin A-induced endo-
derm differentiation is compromised by DKK1 knockdown, which can be rescued by addition of WNT antagonist Xav939 at 
late stage of differentiation. The differentiation process includes 2-day treatment of activin A and Wnt3a followed by another 
2-day treatment with or without Xav939. The differentiation efficiency is measured by quantification of CD184-positive cell 
population after 4-day differentiation.
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that the H3K27me3 level of WNT3 gene promoter is 
increased upon KDM6A or KDM6B knockdown, while 
the H3K4me3 level is not significantly altered, consistent 
with the H3K27me3 demethylase activity of KDM6A/
KDM6B (Figure 3C). Importantly, when WNT3 knock-
down ESCs (Supplementary information, Figure S6, left 
panel) are subjected to endoderm differentiation, they ex-
hibit endoderm differentiation defect similar to KDM6A 
or KDM6B knockdown ESCs (Figure 3D). This differen-
tiation defect can be rescued by treatment with the WNT 
agonist, supporting a role for WNT3 in endoderm dif-
ferentiation (Figure 3D). Collectively, these results dem-
onstrate that WNT3 is an important KDM6A/KDM6B 
target that mediates the function of KDM6A/KDM6B at 
early stage of endoderm differentiation.
DKK1 is a KDM6A/KDM6B target contributing to later 
stage endoderm differentiation
Using a similar strategy, we analyzed the expression 
pattern of 4 WNT antagonist genes with enrichment of 
H3K27me3 in human ESCs (Supplementary information, 
Figure S5). We found that only DKK1 exhibited a dra-
matic upregulation at the late differentiation stage (Figure 
4A). Consistent with the notion that DKK1 is an impor-
tant KDM6A/KDM6B target, knockdown of KDM6A or 
KDM6B results in DKK1 downregulation (Figure 4B). 
In addition, ChIP analysis indicates that the H3K27me3 
level at DKK1 gene enhancer (amplicon #1), but not its 
transcription start site (amplicon #2), is increased upon 
KDM6A or KDM6B knockdown, while the H3K4me3 
level is not significantly altered (Figure 4C), consistent 
with the H3K27me3 demethylase activity of KDM6A/
KDM6B. Importantly, when DKK1 knockdown ESCs 
(Supplementary information, Figure S6, right panel) are 
subjected to endoderm differentiation, they exhibit en-
doderm differentiation defect similar to KDM6A or KD-
M6B knockdown ESCs (Figure 4D). This differentiation 
defect can be rescued by treatment with exogenous WNT 
antagonist Xav939 at late stage of differentiation (Figure 
4D). Collectively, these results demonstrate that DKK1 is 
an important KDM6A/KDM6B target that mediates the 
function of KDM6A/KDM6B at late stage of endoderm 
differentiation. 
In this study, we demonstrate that the H3K27me3 
demethylases KDM6A and KDM6B contribute to defini-
tive endoderm differentiation from human ESCs. The 
fact that sequential treatment with WNT agonist and an-
tagonist can rescue the endoderm differentiation defect 
caused by KDM6A or KDM6B knockdown suggests 
that KDM6A and KDM6B participate in endoderm dif-
ferentiation through regulating WNT signaling pathway. 
Further analysis revealed that KDM6A and KDM6B play 
an important role in the activation of WNT3 and DKK1 
at early and late stage of endoderm differentiation, re-
spectively. Consistent with the notion that KDM6A and 
KDM6B play an important role in modulating the WNT 
signaling pathway, knockdown of KDM6A/KDM6B also 
disrupted the expression of other WNT target genes in re-
sponding to endoderm differentiation (Supplementary in-
formation, Figure S7). These results allow us to propose 
a working model explaining how KDM6A/KDM6B may 
contribute to the endoderm differentiation process (Figure 
5). It appears that the low KDM6A/KDM6B levels in 
human ESCs help maintain the expression of WNT3 at a 
basal level by keeping the repressive mark H3K27me3 at 
a low level. When treated with endoderm inducer such as 
activin A, KDM6A and KDM6B are upregulated, which 
causes removal of the H3K27me3 repressive mark lead-
ing to upregulation of WNT3 gene expression. Upregula-
tion of WNT3 causes activation of the WNT pathway, 
which promotes mesendoderm differentiation in the pres-
ence of activin A. At the late stage of definitive endoderm 
differentiation, WNT antagonist genes such as DKK1 is 
also activated by KDM6A/KDM6B in a similar fashion 
to suppress WNT signaling pathway for mesendoderm 
to definitive endoderm differentiation (Figure 5). Deple-
tion of KDM6A/KDM6B impairs activation of WNT3 
and DKK1 leading to impaired definitive endoderm dif-
ferentiation. Future studies should reveal how KDM6A/
KDM6B achieves precise temporal control of WNT3 and 
DKK1 regulation. 
Definitive endoderm commitment is mainly controlled 
Figure 5 Hypothetic model explaining how KDM6 may contrib-
ute to definitive endoderm differentiation. Treatment of hESCs 
with activin A causes activation of KDM6A and KDM6B, which 
can target and remove the H3K27me3 repressive mark leading 
to upregulation of WNT3. Increased WNT3 causes activation of 
the WNT pathway and promotes mesendoderm differentiation. 
At the late stage of endoderm differentiation, WNT antagonist 
gene DKK1 is activated by KDM6A and KDM6B in a similar 
fashion to suppress WNT signaling pathway for mesendoderm 
to definitive endoderm differentiation. ME, mesendoderm; DE, 
definitive endoderm. 
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by the TGF-β superfamily member, Nodal/activin A, 
which activates SMAD2/3 and SMAD4 transcriptional 
complexes to drive target gene expression [3]. It has been 
reported recently that activin A treatment results in the 
recruitment of KDM6B concomitant with H3K27me3 
reduction at SMAD2/3 target loci during endoderm dif-
ferentiation [24]. Here we extended this study by uncov-
ering WNT genes as targets of KDM6A and KDM6B 
that contribute to the regulation of definitive endoderm 
differentiation. The fact that knockdown of two of the 
KDM6A/KDM6B targets WNT3 and DKK1 impairs 
endoderm differentiation even when activin A signaling 
is still active suggests that KDM6A/KDM6B-mediated 
activation of WNT signaling is important for endoderm 
differentiation. Our study not only uncovered a novel 
function for KDM6A/KDM6B in endoderm differentia-
tion, but also revealed how they contribute to the differ-
entiation process. 
Materials and Methods
Generation of knockdown human ESC lines
Human ESC lines HUES8 (passage 40-60) was cultured in 
Matrigel-coated dishes with mTeSR1 medium according to the 
manual (STEMCELL Technologies). The lentiviral vector system 
is obtained from the NIH AIDS Research and Reference Reagent 
Program. The murine U6-shRNA cassette is inserted into the 
pTY transducing vector. The 19-nt siRNA targeting sites against 
human KDM6A or KDM6B are as follows: KDM6A-KD1, 
GGAAATTCATTTACGACTT; KDM6A-KD2, GGAGTTCTG-
TAATTTCAAA; KDM6B-KD1, GCATCTATCTGGAGAGCAA; 
KDM6B-KD2, GATTCTTTCTATGGGCTTT; KDM6B-KD3, 
GCTCTGGAACTTTCATACT; control-KD, GGAACTTATTTAG-
CAACTT. WNT3 and DKK1 knockdown vectors were purchased 
from Open Biosystems and verified (clone ID: TRCN0000033381 
and TRCN0000033382 for WNT3; TRCN0000033385 for DKK1). 
After lentiviral transfection, stable knockdown cells were selected 
by using 2 μg/ml puromycin based on the construct containing 
puromycin-resistant cassette.
Definitive endoderm differentiation
For definitive endoderm differentiation, human ESCs cultured 
on Matrigel were washed twice by DMEM/F12 and then cultured 
in basal medium (DMEM/F12, 55 μM 2-mercaptoethanol, 1% (vol/
vol) nonessential amino acids, 0.5% (vol/vol) B27 without vitamin 
A (Invitrogen), 0.25% (vol/vol) N2 (Invitrogen)) supplemented 
with 100 ng/ml activin A (PeproTech) and/or other growth factors 
and chemicals as noted. The growth factors and chemicals used 
in this study included murine Wnt3a (PeproTech, 10-50 ng/ml), 
bFGF (PeproTech, 2-10 ng/ml), BMP4 (R&D, 1-10 ng/ml) and 
XAV939 (Tocris, 0.5-1 μM).
Flow cytometry
Cells were dissociated to a single-cell suspension using 0.05% 
trypsin-EDTA or Accutase (StemCell Technologies). For labeling 
of cell surface antigens, cells were incubated with primary anti-
body (APC-conjugated mouse anti-human CD184 IgG, BD; PE-
conjugated mouse anti-human CD117 IgG, BD) or control isotype 
in ice-cold FACS buffer (2% (vol/vol) FBS in PBS) for 30-45 min 
and followed by washing twice. Then cell labeling was analyzed 
using the flow cytometer FACSAria II with FACSDiva software 
version 6.0 (BD Biosciences) and positive or negative cells were 
sorted for further experiments.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from cell cultures using Qiashred-
der and RNeasy mini kits (Qiagen) and treated with RNase-free 
DNase I set according to the manufacturer’s instructions. Total 
RNA (about 1-2 μg per 20 μl reaction) was reverse transcribed 
using SuperScript™ II Reverse Transcriptase (Invitrogen) primed 
with random hexamer oligonucleotides (Promega). Quantitative 
PCR was carried out on CFX384 Real-Time PCR system (Bio-
Rad) using Sso-Fast EvaGreen Supermix (Bio-Rad) according to 
the manufacturer’s instructions. Relative expression levels were 
normalized to GAPDH and calculated using the 2−ΔCt method. All 
primers were purchased from Invitrogen and listed in Supplemen-
tary information, Table S1.
ChIP-qPCR
For ChIP analysis, undifferentiated human ESCs or differenti-
ated cells from knockdown or control were used for H3K27me3 or 
H3K4me3 or H3 ChIP using Imprint® Chromatin Immunoprecipi-
tation Kit (Sigma) according to the manufacturer’s instructions. 
The antibodies used are all polyclonal rabbit IgG and included an-
ti-H3K27me3 (Millipore), anti-H3K4me3 (Millipore) and anti-H3 
(Abcam). Quantitative PCR was carried out as above. The primers 
were designed according to the published H3K27me3 ChIP-seq 
data [16, 17] and listed in Supplementary information, Table S2.
More detailed methods are shown in Supplementary informa-
tion, Data S1.
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